Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of the Stomach × Nivolumab × Clear all
NCT03647969 2024-08-09

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
262 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

Data powered by HemOnc (CC BY 4.0) Colophon âš¡